Tango Therapeutics 2023 Corporate Overview - Precision Oncology Investor Presentation

Tango Therapeutics presents its precision oncology platform focused on targeting tumor suppressor loss, particularly PRMT5 inhibitors synthetic lethal with MTAP deletion. The company outlines its clinical pipeline including lead program TNG908, planned IND filings for 2023, and cash runway extending into 2025. The presentation details the company's discovery platform supporting development of next-generation cancer therapeutics.